Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer.

Martínez-Trufero, Javier

Martínez-Trufero, Javier.

Affiliation

Martínez-Trufero J; Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain.

Cancer Med ; 11 Suppl 1: 5-9, 2022 10.

Article in En | MEDLINE | ID: mdl-36202603

Subject(s)

Adenocarcinoma; Antineoplastic Agents; Thyroid Neoplasms; Adenocarcinoma/drug therapy; Antineoplastic Agents/adverse effects; Humans; Iodine Radioisotopes/therapeutic use; Phenylurea Compounds/adverse effects; Protein Kinase Inhibitors/adverse effects; Quinolines; Thyroid Neoplasms/drug therapy; Thyroid Neoplasms/pathology; Thyroid Neoplasms/radiotherapy

Key words

hepatotoxicity; lenvatinib; radioiodine refractory differentiated thyroid carcinoma; renal impairment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma / Antineoplastic Agents Type of study: Guideline Limits: Humans Language: En Journal: Cancer Med Year: 2022 Document type: Article

Fulltext

XML

PubMed Links

Search on Google